Search
Privacy statement
May 21, 2021
Privacy Statement European Hematology Association
Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).
Non-EHA Funding Opportunities
Here you will find other interesting funding opportunities for European researchers in hematology. If you are interested in adding additional opportunities to this page, please contact research@ehaweb. org.
Read moreLighting the Flame program phases
A full guide to what our Lighting the Flame program involves, including dates of upcoming online workshops and in-person retreats.
Read moreEHA Statement on the Erasmus MC Attack
EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.
Read moreEMA Issues Call for Expressions of Interest for Drug Safety Studies
The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.
Read moreHow to apply for the EHA Mentorship Program
EHA Portal accountTo apply, either as a mentor or a mentee, you must be registered on the EHA Portal (Fluxx).
Read moreMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them.
Read moreLymphoma, multiple myeloma and marrow failure syndromes better understood during Sri Lanka tutorial
Hematologists from Sri Lanka and surrounding countries learned how to best care for patients with lymphoma, multiple myeloma and bone marrow failure syndromes and stem cell transplantation during the joint Tutorial organized by EHA with the Sri Lanka College of…
Read moreIbrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.
Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- »